Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Reviewrac-CCT 250863
Description: Potent Nek2 inhibitor
Chemical Name: 4-[2-Amino-5-[4-[(dimethylamino)methyl]-2-thienyl]-3-pyridinyl]-2-[[(2Z)-4,4,4-trifluoro-1-methyl-2-buten-1-yl]oxy]benzamide
Purity: ≥98% (HPLC)
Biological Activity for rac-CCT 250863
rac-CCT 250863 is a potent Nek2 inhibitor (IC50 = 73 nM). Exhibits selectivity for Nek2 over PLK1, MPS1, Cdk2 and Aurora A.
Technical Data for rac-CCT 250863
| M. Wt | 490.54 |
| Formula | C24H25F3N4O2S |
| Storage | Store at -20°C |
| Purity | ≥98% (HPLC) |
| CAS Number | 1364269-06-6 |
| PubChem ID | 57386035 |
| InChI Key | LLEOOSLUHRQCHZ-SREVYHEPSA-N |
| Smiles | CN(C)CC1=CSC(C2=CN=C(N)C(C3=CC(OC(/C=C\C(F)(F)F)C)=C(C(N)=O)C=C3)=C2)=C1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for rac-CCT 250863
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| 1eq. HCl | 49.05 | 100 | |
| DMSO | 49.05 | 100 |
Preparing Stock Solutions for rac-CCT 250863
The following data is based on the product molecular weight 490.54. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.04 mL | 10.19 mL | 20.39 mL |
| 5 mM | 0.41 mL | 2.04 mL | 4.08 mL |
| 10 mM | 0.2 mL | 1.02 mL | 2.04 mL |
| 50 mM | 0.04 mL | 0.2 mL | 0.41 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Product Datasheets for rac-CCT 250863
References for rac-CCT 250863
References are publications that support the biological activity of the product.
Innocenti et al (2012) Design of potent and selective hybrid inhibitors of the mitotic kinase Nek2: structure-activity relationship, structural biology, and cellular activity. J.Med.Chem. 55 3228 PMID: 22404346
If you know of a relevant reference for rac-CCT 250863, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: rac-CCT 250863, rac-CCT 250863 supplier, rac-CCT250863, potent, NEK2, inhibitors, inhibits, selective, never-in-mitosis-gene-a-related, kinases, Nek2, Kinase, 4546, Tocris Bioscience
Citations for rac-CCT 250863
Citations are publications that use Tocris products.
Currently there are no citations for rac-CCT 250863. Do you know of a great paper that uses rac-CCT 250863 from Tocris? Please let us know.
Reviews for rac-CCT 250863
There are currently no reviews for this product. Be the first to review rac-CCT 250863 and earn rewards!
Have you used rac-CCT 250863?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Angiogenesis in Cancer Poster
This poster summarizes the pathogenesis of angiogenesis in cancer, as well as some of the main angiogenesis therapeutic targets.
Cancer Metabolism Poster
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.
Cell Cycle & DNA Damage Repair Poster
In normal cells, each stage of the cell cycle is tightly regulated, however in cancer cells many genes and proteins that are involved in the regulation of the cell cycle are mutated or over expressed. This poster summarizes the stages of the cell cycle and DNA repair. It also highlights strategies for enhancing replicative stress in cancer cells to force mitotic catastrophe and cell death.
Epigenetics in Cancer Poster
This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.